Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer (Q35791273)
scientific article published on April 2004
Language:
Current Data About Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer
(P31) (Q13442814)
(P248)
(P698) 15176001
(P813) Thursday, August 10, 2017

(P50) (Q88547480)
(P1545) 3
(P1932) Christopher J Logothetis
(P248)
(P698) 15176001
(P813) Thursday, August 10, 2017

(P304) 24-29
(P248)
(P698) 15176001
(P813) Thursday, August 10, 2017

(P433) 2 Suppl 6
(P248)
(P698) 15176001
(P813) Thursday, August 10, 2017

(P478) 31
(P248)
(P698) 15176001
(P813) Thursday, August 10, 2017

(P577) Thursday, April 1, 2004
(P248)
(P698) 15176001
(P813) Thursday, August 10, 2017

(P921) (Q420436)
(P887)

(Q177094)
(P887)

(Q181257)
(P887)

(P1433) (Q14330412)
(P248)
(P698) 15176001
(P813) Thursday, August 10, 2017

(P1476) "Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer" (language: en)
(P248)
(P698) 15176001
(P813) Thursday, August 10, 2017

(P2093) Paul Mathew
(P1545) 1
(P248)
(P698) 15176001
(P813) Thursday, August 10, 2017

Isaiah J Fidler
(P1545) 2
(P248)
(P698) 15176001
(P813) Thursday, August 10, 2017

(P13046) (Q7318358)
(P248)

other details
description scientific article published on April 2004

External Links
(P356) 10.1053/J.SEMINONCOL.2004.03.037
(P698) 15176001